Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of April 2021.

An explanation of the WTO waiver of COVID-19 intellectual property, what the U.S. declaration of support means, and likely effects of the waiver.

Should a waiver be issued, there is no legal mechanism that can compel the transfer of certain types of know-how or trade secrets.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of March 2021.

Senator Lisa Murkowski’s reintroduction of the Safe Step Act has revived the debate over the prudence of step therapy protocols.

The exclusion of pregnant people from clinical trials has led to inequities in health care during pregnancy.

Drone-enabled pharmaceutical delivery offers a number of advantages over its low-tech forebears, not least including patient convenience.

A U.S. District Court recently halted the implementation of a dispute resolution rule for the 340B Drug Pricing Program.

Patients may face increased out-of-pocket drug costs as a result of a rule finalized by the Centers for Medicare & Medicaid Services in July 2020.
